SCHEMBL5694198

SCHEMBL5694198

Nc1nc(C(=O)COc2ccccc2)nc2[nH]cnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.40
GAA P10253 2/20 0.38
NPC1 O15118 4/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ADORA3 P0DMS8 2/20 0.38
ADORA2A P29274 2/20 0.38
RAB9A P51151 2/20 0.38
TP53 P04637 1/20 0.38
ALOX12 P18054 1/20 0.38
KMT2A Q03164 4/20 0.37
ALPL P05186 2/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALPI P09923 1/20 0.37
ALPG P10696 1/20 0.37
ADORA1 P30542 1/20 0.37
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16401527 0.85 RAB9A (0.42) NPC1ALDH1A1RAB9AKMT2AMEN1
SCHEMBL5694207 0.80 PDPK1 (0.43) ALOX15ALDH1A1LMNAPOLBHPGD
SCHEMBL453562 0.78 POLB (0.44) GAANPC1ALDH1A1SMN1; SMN2RAB9A
SCHEMBL8581230 0.77 KMT2A (0.45) ADORA2AKMT2AMEN1MAPTKDM4E
SCHEMBL1684047 0.76 GDA (0.38) GAAKMT2AKDM4E
SCHEMBL9393663 0.75 ADORA2A (0.46) GAAADORA2ALMNAADORA1
SCHEMBL5694071 0.72 KMT2A (0.41) ALOX15GAANPC1ALDH1A1SMN1; SMN2
SCHEMBL3630345 0.72 GDA (0.37) GAA
SCHEMBL4160288 0.72 ADORA2A (0.41) ALDH1A1ADORA3ADORA2AKMT2AMEN1
SCHEMBL5468651 0.71 XDH (0.41) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3004131-B1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2020-07-22 EP claimed
EP-3004131-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM Chemicals Llc (US) 2016-04-13 EP claimed
US-20160083414-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2016-03-24 US claimed
WO-2014197714-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2014-12-11 WO claimed
EP-3004131-B1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2020-07-22 EP disclosed
US-10669301-B2 Phosphoramidite building blocks for sugar-conjugated oligonucleotides AM CHEMICALS LLC (US) 2020-06-02 US disclosed
US-20180362572-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2018-12-20 US disclosed
US-10087208-B2 Phosphoramidite building blocks for sugar-conjugated oligonucleotides AM CHEMICALS LLC (US) 2018-10-02 US disclosed
EP-3004131-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM Chemicals Llc (US) 2016-04-13 EP disclosed
US-20160083414-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2016-03-24 US disclosed
WO-2014197714-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2014-12-11 WO disclosed
US-20140038181-A1 CHEMICALLY SUBSTITUTED THERMOSENSITIVE PROBES AND COFACTORS FOR HOT START LIGATION TRILINK BIOTECHNOLOGIES, INC. 2014-02-06 US disclosed
WO-2012094343-A1 CHEMICALLY SUBSTITUTED THERMOSENSITIVE PROBES AND COFACTORS FOR HOT START LIGATION TRILINK BIOTECHNOLOGIES (US) 2012-07-12 WO disclosed
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside MITSUI CHEMICALS, INC. (JP) 2006-07-27 US disclosed
EP-1645561-A1 METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE Mitsui Chemicals, Inc. (JP) 2006-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669301-B2 Phosphoramidite building blocks for sugar-conjugated oligonucleotides DERA, FBP1, PNKP ALOX15 2470/4885GAA 597/4885NPC1 4018/4885
US-20180362572-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES DERA, TYMP, PAICS ALOX15 2425/4885GAA 593/4885NPC1 4187/4885
US-10087208-B2 Phosphoramidite building blocks for sugar-conjugated oligonucleotides DERA, TYMP, PAICS ALOX15 2425/4885GAA 593/4885NPC1 4187/4885
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside NSUN2, POLR2H, POLB ALOX15 3856/4885GAA 3189/4885NPC1 2171/4885
US-20160083414-A1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES DERA, TYMP, PAICS ALOX15 2425/4885GAA 593/4885NPC1 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.